10-K: OSR Holdings Reports Increased Losses Amid Strategic Shifts

OSR Holdings, Inc. reported a significant increase in net loss for fiscal year 2025, driven by higher operating expenses and one-time merger-related costs, while advancing its biotech pipeline and expanding its medical device distribution business.

Summary

• Net loss for the year ended December 31, 2025, increased to $27.06 million, up from $10.33 million in 2024.
• Operating loss increased by 57% to $18.34 million in 2025, compared to $11.69 million in 2024.
• Selling, General, and Administrative (SG&A) expenses rose by 51% to $18.93 million in 2025, primarily due to professional service fees and personnel costs related to the business combination.
• Other expenses surged by $10.35 million, largely due to $8.5 million in non-cash merger-related expenses and $4.8 million in expenses from warrants and convertible notes with White Lion Capital.
• Cash and cash equivalents stood at $1.7 million as of December 31, 2025, up from $0.34 million in 2024.
• The company completed its business combination with OSR Holdings Co., Ltd. (OSRK) on February 14, 2025, and changed its name to OSR Holdings, Inc.
• Vaximm AG, a subsidiary, entered a binding term sheet with BCM Europe AG for an exclusive global license of the VXM01 oral cancer immunotherapy platform, including a $30 million upfront payment ($15 million cash, $15 million digital assets) and up to $815 million in milestone payments.
• OSRK acquired Woori IO Co., Ltd., a South Korea-based medical device company developing non-invasive biosensing technology for glucose monitoring, on January 26, 2026.
• RMC, the medical device distribution subsidiary, saw net sales decrease by 18% to $2.91 million in 2025, due to changes in supplier contracts and increased product costs.
• RMC is strategically transforming into a fourth-party logistics (4PL) platform for the Korean healthcare supply chain, with projected revenue growth from KRW 4.1 billion in 2026 to KRW 44.8 billion in 2030.
• Research and Development (R&D) expenses increased by 98% to $318,446 in 2025, mainly for Darnatein's cGMP facility maintenance.
• The company received a Nasdaq notice for non-compliance with the minimum bid price rule ($1.00) on September 5, 2025, and has an extended deadline until August 31, 2026, to regain compliance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a negative sentiment due to significantly increased losses, declining core business revenue, and identified material weaknesses in internal controls. While strategic initiatives and biotech pipeline progress offer long-term potential, the immediate financial challenges and Nasdaq compliance issues present substantial near-term risks.

Positives

• Successful completion of the business combination with OSR Holdings Co., Ltd., transitioning from a blank check company to an operating entity.
• Vaximm AG secured a significant global license agreement for its VXM01 oral cancer immunotherapy platform, including a $30 million upfront payment and potential milestones up to $815 million.
• VXM01 has Orphan Drug Designation from the FDA and EMA for glioblastoma and pancreatic cancer, offering potential market exclusivity.
• Darnatein's DRT-102 showed promising results in a confirmatory clinical trial for lumbar spinal fusion, with a 75% bone fusion rate in the test group compared to 25% in the control group.
• The acquisition of Woori IO Co., Ltd. expands the company's portfolio into non-invasive biosensing technology for glucose monitoring, including a technology development collaboration with Samsung Electronics.
• RMC's strategic shift to a 4PL platform in Korea presents a significant new growth engine with substantial projected revenue growth through 2030.
• The company successfully regained compliance with Nasdaq's Minimum Public Holders Rule in March 2025.

Negatives

• The company incurred a significant net loss of $27.06 million in 2025, a 143% increase from 2024.
• Operating loss increased by 57% to $18.34 million in 2025.
• Net sales decreased by 18% in 2025, primarily due to changes in RMC's supplier contracts and increased product costs.
• Gross profit declined by 27% in 2025.
• Substantial doubt exists about the company's ability to continue as a going concern due to recurring operating losses and negative cash flows.
• Material weaknesses in internal control over financial reporting were identified as of December 31, 2025, related to liabilities completeness/accuracy and insufficient accounting personnel.
• The company received a Nasdaq notice for non-compliance with the minimum bid price requirement ($1.00) and faces potential delisting if compliance is not regained by August 31, 2026.
• The ELOC agreement could result in significant dilution for existing shareholders.
• The company is currently involved in two civil actions seeking substantial brokerage fees and damages, totaling over $2.4 million.

Risks

• The price of the company's common stock and warrants may be volatile and has declined significantly, increasing the risk of delisting and making future financing more difficult and dilutive.
• The company has a limited operating history and early-stage development programs, making it difficult to execute its business model and achieve profitability.
• Substantial additional capital will be required to finance operations, and failure to raise it could force delays or elimination of research and development programs.
• The company has no marketing and sales organization for pharmaceutical products and may struggle to commercialize products if unable to establish these capabilities or secure third-party agreements.
• Investment strategy and future growth rely on assumptions that may not be realized, potentially impacting market acceptance and profitability of product candidates.
• The company's future success depends on retaining key employees and attracting qualified personnel in a competitive biotechnology industry.
• Reliance on a central team of limited employees for all subsidiaries presents operational challenges and potential for ineffective management.
• The company's significant operations and assets in South Korea expose it to political, economic, legal, and regulatory risks, including currency fluctuations and potential secondary tax liability.
• Conflicts of interest may arise from related-party relationships, potentially affecting licensing terms and royalty revenues.
• The company's principal stockholders and management own a significant percentage of common stock, allowing them to exert substantial control over stockholder approval matters.
• Lack of business diversification, with prospects largely dependent on the healthcare sector, exposes the company to industry-specific negative developments.
• The company may be subject to product liability or other product claim risks, and current insurance may be insufficient.
• Relationships with healthcare providers and third-party payors are subject to anti-kickback, fraud, and abuse laws, potentially leading to criminal sanctions or civil penalties.
• Ongoing regulatory obligations and review for approved products may result in significant additional expense and penalties for non-compliance.
• The Affordable Care Act and Inflation Reduction Act, along with other healthcare reform measures, may adversely affect drug pricing and profitability.
• International operations expose the company to higher costs, currency exchange rules, tariffs, trade barriers, and ineffective intellectual property protection in certain countries.
• Inability to obtain and maintain patent and other intellectual property protection, or challenges to existing patents, could harm competitive position.
• Failure to protect the confidentiality of trade secrets could harm business and competitive position.
• The company is an early-stage company without significant investments in data security protection and may not be sufficiently protected against cybersecurity incidents.

Future Outlook

The company aims to build a robust portfolio of innovative and potentially transformative therapies and healthcare solutions by acquiring and operating innovative healthcare-related companies globally. RMC is transforming into a 4PL platform in Korea, projecting significant revenue growth from KRW 4.1 billion in 2026 to KRW 44.8 billion in 2030. Vaximm anticipates its next oral cancer vaccine candidate beyond VXM01 could enter clinical trials within 3-5 years, with potential regulatory approval in less than 7 years, and significantly shorter timelines (about 4 years) for the improved VXM01 version. Darnatein expects its first therapeutic regimen to enter clinical trials within 2-3 years, with potential regulatory approval in 8-11 years. The company plans to introduce new, less dilutive equity financing facilities like At-the-Market (ATM) offerings following this 10-K filing.

Management Comments

• Management views RMC's 4PL transformation as one of the most significant value creation opportunities within the OSR Holdings portfolio.
• Management believes RMC is positioned to execute its roll-up strategy promptly upon capital allocation by OSR Holdings.
• Management is committed to maintaining a strong internal control environment and has initiated measures designed to remediate the material weaknesses identified in internal control over financial reporting.

Industry Context

StockSavvy.ai notes that OSR Holdings operates in highly competitive and capital-intensive sectors of the healthcare industry, including oncology, regenerative medicine, and medical device distribution. The strategic shift of its RMC subsidiary into a 4PL platform in South Korea addresses structural stresses in the local medical device import and distribution sector, such as foreign exchange pressure and working capital mismatches, positioning it as a consolidator in a fragmented market. This move aligns with broader trends of supply chain optimization and market consolidation in mature healthcare markets. The company's biotech subsidiaries, Vaximm and Darnatein, are pursuing innovative therapies in oncology and degenerative diseases, areas with high unmet medical needs and significant R&D investment from major pharmaceutical and biotechnology companies globally, such as AbbVie, AstraZeneca, Bayer, Medtronic, and Stryker. The acquisition of Woori IO, focusing on non-invasive glucose monitoring, taps into the growing demand for digital health and personalized medicine, particularly relevant in aging populations.

Comparison to Industry Standards

• Vaximm's VXM01, an oral T-cell immunotherapy for glioblastoma, is in late clinical-stage development (Phase 2 completed, Phase 2/3 planned). Competitors like AbbVie (Depatuxizumab mafodotin), AstraZeneca (Durvalumab), and VBL Therapeutics (Ofranergene obadenovec) have products in Phase 2 or Phase 3 for glioblastoma, indicating a competitive landscape for late-stage oncology assets.
• Darnatein's DRT-102 for spinal fusion demonstrated a 75% bone fusion rate in its confirmatory clinical trial, which compares to commercialized orthopedic solutions like Medtronic's Infuse Bone Graft (rhBMP-2), NuVasive's Osteocel Plus (DBM and MSC), and Stryker's Bio4 (viable bone matrix). The reported efficacy suggests a competitive profile, though direct head-to-head comparisons are not provided.
• Darnatein's DRT-101 for osteoarthritis is in preclinical development. The DMOAD (Disease-Modifying Osteoarthritis Drugs) market is highly competitive with companies like Kolon TissueGene (Invossa), Biosplice Therapeutics (Lorecivivint), and Merck KGaA/EMD Serono (Sprifermin) having candidates in Phase 2 or Phase 3, indicating a long development pathway for DRT-101 to reach market.
• RMC's medical device distribution business in Korea faces competition from major international brands like Medtronic, Stryker, Microvention, and Boston Scientific in the neurovascular intervention market. RMC's transformation into a 4PL platform aims to differentiate itself by addressing local market inefficiencies, a strategy that could provide a competitive advantage against global players focused primarily on product sales.

Management Changes

Corporate Governance

Legal Proceedings

• Benjamin Securities, Inc. filed a civil action in Supreme Court, New York County, seeking $425,000 in brokerage fees and costs. The matter remains pending as of September 30, 2025.
• Chardan Capital Markets, LLC filed a complaint in the United States District Court for the Southern District of New York on September 2, 2025, seeking $2,070,000 in damages for breach of contract. Settlement discussions are ongoing while discovery proceeds.

Related Party Transactions

• The company pays an affiliate of its Sponsor, BCM, $7,500 per month for office space, utilities, and secretarial/administrative support, which continued after the business combination.
• A Venture Partner Agreement with Josh Pan (an individual member of Bellevue Capital Management, LLC, which wholly owns the Sponsor) provides a monthly advisory fee of $15,000 for strategic and scientific advisory services.
• Dr. Constance Hfer, Chief Scientific Officer, has a consulting agreement with the company for EUR300,000 per year; she previously provided services to Vaximm AG through BCM Europe AG.
• Non-employee directors receive an annual cash board fee of $50,000, effective February 2025.
• Promissory notes with related parties: Jun Chul Whang ($45,000 outstanding), Josh Pan ($60,000 outstanding), Bellevue Global Life Sciences Investors, LLC (BGLSI) ($715,000, $23,000, $140,000, $280,000 outstanding from various notes), and BCM Europe AG ($60,000 outstanding). Most of these notes have maturity dates extended to December 31, 2026, with the BCME note maturing November 14, 2027.
• The company advanced loans totaling $2,909,000 to its subsidiary OSR Holdings Co., Ltd. (OSRK) for working capital and operating expenses, consisting of $175,000 interest-bearing and $2,734,000 non-interest-bearing advances.

Stakeholder Impact

• Shareholders face significant dilution risk from the Equity Line of Credit (ELOC) agreement and potential future equity raises.
• Shareholders are exposed to increased financial risk due to recurring operating losses, negative cash flows, and substantial doubt about the company's going concern ability.
• The Nasdaq minimum bid price non-compliance and potential delisting could negatively impact shareholder liquidity and stock value.
• Employees and management may face increased workload and pressure due to the company's growth initiatives, integration of new subsidiaries, and compliance requirements as a public company.
• Customers of RMC may experience changes in product availability or service as the subsidiary transitions its distribution model and seeks new manufacturing partners.
• Creditors face increased risk due to the company's substantial operating losses and reliance on future financing to meet its obligations.
• The global license agreement for VXM01 could provide long-term value for shareholders if milestones and royalties are realized, but the recovery mechanism for BCME may delay direct benefits to Vaximm.

Next Steps

• Vaximm plans to initiate new Phase 2 and Phase 2/3 clinical trials for VXM01 in recurrent glioblastoma patients in 2026.
• Vaximm will continue to evaluate other preclinical candidates (VXM04, VXM06, VXM08, VXM10) for further development in IND-enabling studies.
• Darnatein intends to continue development and testing of DRT-101 and, when additional resources are available, DRT-102, with the first therapeutic regimen expected to enter clinical trials within 2-3 years.
• RMC plans to execute its 4PL roll-up strategy promptly upon capital allocation by OSR Holdings, with 4PL revenue projected to commence in 2027.
• The company will monitor its common stock's closing bid price and may pursue options like a reverse stock split to regain Nasdaq compliance by August 31, 2026.
• Management is continuing to implement measures to remediate identified material weaknesses in internal control over financial reporting.
• The company plans to introduce new equity financing facilities, such as At-the-Market (ATM) offerings, following the filing of this Form 10-K.
• The R&D Committee, instituted in January 2026, will review and provide guidance on the company's overall research and development strategy and oversee program progress.

Key Dates

Recommendation

A seasoned investor or institution would likely recommend 'sell' for OSR Holdings based on this filing. The company exhibits severe financial distress, marked by a 143% increase in net loss, a 57% rise in operating loss, and declining core business revenue. The auditor's 'going concern' warning highlights fundamental solvency issues. While strategic acquisitions and biotech pipeline progress offer long-term potential, the immediate need for substantial capital, coupled with significant dilution risk from the ELOC and potential future equity raises, creates an unfavorable risk-reward profile. Furthermore, the Nasdaq minimum bid price non-compliance and ongoing legal proceedings add layers of uncertainty and potential for further share price depreciation. The identified material weaknesses in internal controls also raise concerns about financial reporting reliability. The positive developments are overshadowed by the critical financial and operational challenges.

Keywords

Healthcare, Biotechnology, Pharmaceuticals, Medical Devices, Oncology, Immunotherapy, Glioblastoma, Pancreatic Cancer, Degenerative Diseases, Osteoarthritis, Spinal Fusion, Biosensing Technology, Glucose Monitoring, SEC Filing, 10-K, Nasdaq, Clinical Trials, Orphan Drug, Intellectual Property, South Korea, 4PL Logistics, Capital Raise, Going Concern, Vaximm, Darnatein, RMC, Woori IO